Overexpression of myosin phosphatase reduces Ca2+ sensitivity of contraction and impairs cardiac function

Circulation Journal

Volumn 74, Issue 1, 2010, Pages 120-128

  Mizutani, Hideo ^a   Okamoto, Ryuji ^a   Moriki, Nobuyuki ^a   Konishi, Katsuhisa ^a   Taniguchi, Masaya ^a   Fujita, Satoshi ^a   Dohi, Kaoru ^a   Onishi, Katsuya ^a   Suzuki, Noboru ^b   Satoh, Shinji ^c   Makino, Naoki ^d   Itoh, Takeo ^e   Hartshorne, David J ^f   Ito, Masaaki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Ca2+ sensitization; Myocardial contraction; Myosin light chain; Myosin phosphatase; Transgenic mouse

Indexed keywords

BETA ESCIN; CALCIUM; CARDIAC MYOSIN; HOLOENZYME; MYOSIN HEAVY CHAIN ALPHA; MYOSIN PHOSPHATASE TARGET SUBUNIT 2; PHOSPHATASE; TYPE 1 PHOSPHATASE CATALYTIC SUBUNIT DELTA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; DESENSITIZATION; GENE OVEREXPRESSION; HEART; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERMEABILITY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIZATION; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; FEMALE; HEART; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN SUBUNITS;

EID: 75149138356     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0462     Document Type: Article

References (39)

1. Hartshorne DJ. Biochemistry of the contractile process in smooth muscle. In: Johnson LR, editor. Physiology of the gastrointestinal tract. New York: Raven Press; 1987; 432-482.
2. Sweeney HL, Bowman BF, Stull JT. Myosin light chain phosphorylation in vertebrate striated muscle: Regulation and function. Am J Physiol 1993; 264: C1085-C1095.
3. Ito M, Nakano T, Erdödi F, Hartshorne DJ. Myosin phosphatase: Structure, regulation and function. Mol Cell Biochem 2004; 259: 197-209.
4. Hartshorne DJ, Ito M, Erdödi F. Role of protein phosphatase type 1 in contractile functions: Myosin phosphatase. J Biol Chem 2004; 279: 37211-37244.
5. Seguchi O, Takashima S, Yamazaki S, Asakura M, Asano Y, Shintani Y, et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest 2007; 117: 2812-2824.
6. Takashima S. Phosphorylation of myosin regulatory light chain by myosin light chain kinase, and muscle contraction. Circ J 2009; 73: 208-213.
7. Okamoto R, Kato T, Mizoguchi A, Takahashi N, Nakakuki T, Mizutani H, et al. Characterization and function of MYPT2, a target subunit of myosin phosphatase in heart. Cell Signal 2006; 18: 1408-1416.
8. Davis JS, Hassanzadeh S, Winitsky S, Lin H, Satorius C, Vemuri R, et al. The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell 2001; 107: 631-641.
9. Aoki H, Sadoshima J, Izumo S. Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro. Nat Med 2000; 6: 183-188.
10. 2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 2003; 57: 37-47.
11. 2+ sensitivity in failing hearts. Am J Physiol Heart Circ Physiol 2001; 281: H637-H646.
12. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 1991; 266: 9180-9185.
13. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273: 245-248.
14. Fujioka M, Takahashi N, Odai H, Araki S, Ichikawa K, Feng J, et al. A new isoform of human myosin phosphatase targeting/regulatory subunit (MYPT2): cDNA cloning, tissue expression, and chromosomal mapping. Genomics 1998; 49: 59-68.
15. Shima H, Hatano Y, Chun YS, Sugimura T, Zhang Z, Lee EY, et al. Identification of PP1 catalytic subunit isotypes PP1 gamma 1, PP1 delta and PP1 alpha in various rat tissues. Biochem Biophys Res Commun 1993; 192: 1289-1296.
16. Arimura T, Suematsu N, Zhou YB, Nishimura J, Satoh S, Takeshita A, et al. Identification, characterization, and functional analysis of heart-specific myosin light chain phosphatase small subunit. J Biol Chem 2001; 276: 6073-6082.
17. Ito M, Dabrowska R, Guerriero V Jr, Hartshorne DJ. Identification in turkey gizzard of an acidic protein related to the C-terminal portion of smooth muscle myosin light chain kinase. J Biol Chem 1989; 264: 13971-13974.
18. Nishio R, Sasayama S, Matsumori A. Left ventricular pressurevolume relationship in a murine model of congestive heart failure due to acute viral myocarditis. J Am Coll Cardiol 2002; 40: 1506-1514.
19. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 2003; 35: 59-70.
20. Hartshorne DJ, Ito M, Erdodi F. Myosin light chain phosphatase: Subunit composition, interactions and regulation. J Muscle Res Cell Motil 1998; 19: 325-341.
21. Steenaart NA, Ganim JR, Di Salvo J, Kranias EG. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch Biochem Biophy 1992; 293: 17-24.
22. Champion HC. Targeting protein phosphatase 1 in heart failure. Circ Res 2005; 96: 708-710.
23. Aschenbach WG, Suzuki Y, Breeden K, Prats C, Hirshman MF, Dufresne SD, et al. The muscle-specific protein phosphatase PP1G/ RGL(GM)is essential for activation of glycogen synthase by exercise. J Biol Chem 2001; 276: 39959-39967.
24. Zhi G, Ryder JW, Huang J, Ding P, Chen Y, Zhao Y, et al. Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. Proc Natl Acad Sci USA 2005; 102: 17519-17524.
25. Rajashree R, Blunt BC, Hofmann PA. Modulation of myosin phosphatase targeting subunit and protein phosphatase 1 in the heart. Am J Physiol Heart Circ Physiol 2005; 289: H1736-H1743.
26. 2+ sensitivity of force and activation dependence of the kinetics of myocardial force development. Am J Physiol Heart Circ Physiol 2004; 287: H2712-H2718.
27. Kimura A. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J 2008; 72(Suppl A): A-38-A-48.
28. Harada M, Takeishi Y, Arimoto T, Niizeki T, Kitahara T, Goto K, et al. Diacylglycerol kinase ζ attenuates pressure overload-induced cardiac hypertrophy. Circ J 2007; 71: 276-282.
29. Niizeki T, Takeishi Y, Kitahara T, Arimoto T, Koyama Y, Goto K, et al. Diacylglycerol kinase zeta rescues G alpha q-induced heart failure in transgenic mice. Circ J 2008; 72: 309-317.
30. Fitzsimons DP, Bodell PW, Baldwin KM. Myocardial functional correlates of cardiac myosin light chain 2 phosphorylation. J Appl Physiol 1990; 68: 2426-2433
31. Sanbe A, Fewell JG, Gulick J, Osinska H, Lorenz J, Hall DG, et al. Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2. J Biol Chem 1999; 274: 21085-21094.
32. Scruggs SB, Hinken AC, Thawornkaiwong A, Robbins J, Walker LA, de Tombe PP, et al. Ablation of ventricular myosin regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and affects neighboring myofilament protein phosphorylation. J Biol Chem 2009; 284: 5097-6006.
33. Jideama NM, Noland TA Jr, Raynor RL, Blobe GC, Fabbro D, Kazanietz MG, et al. Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. J Biol Chem 1996; 271: 23277-23283.
34. 2+ sensitizers. Circ J 2008; 72: 1915-1925.
35. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305-315.
36. Palmer BM. Thick filament proteins and performance in human heart failure. Heart Fail Rev 2005; 10: 187-197.
37. Takano H, Hasegawa H, Nagai T, Komuro I. Implication of cardiac remodeling in heart failure: Mechanisms and therapeutic strategies. Intern Med 2003; 42: 465-469.
38. Morano I. Tuning the human heart molecular motors by myosin light chains. J Mol Med 1999; 287: 544-555.
39. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 2007; 101: 85-94.